SPIRE – combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial

Abstract Background Urothelial bladder cancer (UBC) accounts for 10,000 new diagnoses and 5000 deaths annually in the UK (Cancer Research UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bladder-cancer, Cancer Research UK, Accessed 26 Mar 2018). Cis...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Simon Crabb, Sarah J. Danson, James W. F. Catto, Cathy McDowell, James N. Lowder, Joshua Caddy, Denise Dunkley, Jessica Rajaram, Deborah Ellis, Stephanie Hill, David Hathorn, Amy Whitehead, Mihalis Kalevras, Robert Huddart, Gareth Griffiths
Format: Artigo
Idioma:Inglês
Publicat: BMC 2018-04-01
Col·lecció:Trials
Matèries:
Urothelial bladder cancer
Guadecitabine
DNA methyltransferase inhibitor
Phase I/II
Randomised controlled trial
Cisplatin resistance
Accés en línia:http://link.springer.com/article/10.1186/s13063-018-2586-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars